Adults 18 to 80, any sex, with Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Adverse Events Related to Study TreatmentPrimary· Up to 12 months
Number of Participants with NCI CTCAE Version 4.0 Adverse Events related to study treatment greater than or equal to Grade 3
Group
Value
95% CI
NY-ESO-1ᶜ²⁵⁹T Cells Administered IV
2
Evaluate the Direct Anti-tumor Activity of NY-ESO-1ᶜ²⁵⁹TSecondary· 180 days
Number of participants with response post-infusion as assessed by international uniform response criteria
Group
Value
95% CI
NY-ESO-1ᶜ²⁵⁹T Cells Administered IV
0
Peak Persistence of Modified T-cells in the Peripheral BloodSecondary· Days 1, 3, 5, 8, 15, 22, 29, 43, 101, 130 181, every 3 months thereafter
Measurement of NY-ESO-1ᶜ²⁵⁹T cells in blood (copies of WPRE per µg of genomic PBMC DNA)
Group
Value
95% CI
NY-ESO-1ᶜ²⁵⁹T Cells Administered IV
29,179
4479 – 53,879
Adverse events — posted to ClinicalTrials.gov
Time frame: Start of lymphodepletion to end of intervention phase (up to 12 months post T-cell infusion).
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
NY-ESO-1ᶜ²⁵⁹T Cells Administered IV
Serious: 1/2 (50%)
Deaths: 2/2
Serious adverse events (1 terms)
Reaction
System
NY-ESO-1ᶜ²⁵⁹T Cells Admini…
Humerus fracture
Injury, poisoning and procedural complications
—
Other adverse events (11 terms — click to expand)
Reaction
System
NY-ESO-1ᶜ²⁵⁹T Cells Admini…
White blood cell count decreased
Investigations
—
Lymphocyte count decreased
Investigations
—
Neutrophil count decreased
Investigations
—
Anemia
Blood and lymphatic system disorders
—
Aspartate aminotransferase increased
Investigations
—
Benign neoplasm
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma
· Phase 1
· recruiting
NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
· Phase 1
· recruiting
NCT07454382 — A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma
· Phase 2
· recruiting
NCT07266441 — A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
· Phase 2
· recruiting
NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With
· Phase 3
· recruiting
Other Adaptimmune trials
Trials by the same sponsor.
NCT04752358 — ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2)
· Phase 2
· terminated
NCT06048705 — Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Lipo
· Phase 1
· terminated
NCT04526509 — Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or L
· Phase 1
· terminated
NCT05943990 — Study of GSK3845097 in Previously Treated Participants With Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
· Phase 1
· terminated
NCT03391791 — Long Term Follow up of Subjects Exposed to Genetically Engineered T Cell Receptors
· terminated
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Adaptimmune
Last refreshed: 10 January 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01892293.